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Myocardial Recovery and the Failing Heart
Myth, Magic, or Molecular Target?
Douglas L. Mann, MD,* Philip M. Barger, MD,* Daniel Burkhoff, MD, PHD†
St. Louis, Missouri; and New York, New York
Medical and device therapies that reduce heart failure morbidity and mortality also lead to decreased left ven-
tricular volume and mass and a more normal elliptical shape of the ventricle. These are due to changes in myo-
cyte size, structure, and organization that have been referred to collectively as reverse remodeling. Moreover,
there are subsets of patients whose hearts have undergone reverse remodeling either spontaneously or after
medical or device therapies and whose clinical course is associated with freedom from future heart failure
events. This phenomenon has been referred to as myocardial recovery. Despite the frequent interchangeable
use of the terms “myocardial recovery” and “reverse remodeling” to describe the reversal of various aspects of
the heart failure phenotype after medical and device therapy, the literature suggests that there are important
differences between these 2 phenomena and that myocardial recovery and reverse remodeling are not synony-
mous. In this review, we discuss the biology of cardiac remodeling, cardiac reverse remodeling, and myocardial
recovery with the intent to provide a conceptual framework for understanding myocardial recovery. (J Am Coll
Cardiol 2012;60:2465–72) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.06.062Clinical studies have shown that medical and device thera-
pies that reduce heart failure morbidity and mortality also
lead to decreased left ventricular (LV) volume and mass and
restore a more normal elliptical shape to the ventricle. These
salutary changes represent the summation of a series of
integrated biological changes in cardiac myocyte size and
function, as well as modifications in LV structure and
organization that are accompanied by shifts of the LV
end-diastolic pressure–volume relationship (EDPVR) to-
ward normal. For want of better terminology, these changes
have been referred to collectively as reverse remodeling
(1,2). It has also become clear that there are subsets of
patients whose hearts have undergone reverse remodeling
either spontaneously or after medical or device therapies and
whose clinical course is associated with freedom from future
heart failure events. This latter phenomenon is referred to as
myocardial recovery (3). The exciting observations with
respect to reverse remodeling and myocardial recovery have
engendered a great deal of interest, insofar as they may
provide important new insights into the development of
novel therapies that are designed to reverse and/or possibly
cure heart failure as opposed to the current therapeutic
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accepted June 12, 2012.approaches that focus on preventing disease progression by
blocking the body’s homeostatic responses (e.g., neurohor-
monal activation). Despite the frequent interchangeable use
of the terms “myocardial recovery” and “reverse remodeling”
to describe the reversal of various aspects of the heart failure
phenotype after medical and device therapy, the extant
literature suggests that there are important differences be-
tween these 2 phenomena and that myocardial recovery and
reverse remodeling are not synonymous. Although there is
abundant phenomenological annotation of the components
of reverse remodeling, it is unclear at the time of this writing
what components of the process of reverse remodeling are
necessary to achieve myocardial recovery. In this review, we
discuss the biology of cardiac remodeling, cardiac reverse
remodeling, and myocardial recovery, with the intent to
provide a conceptual framework for understanding myocar-
dial recovery.
Cardiac Remodeling
The term “LV remodeling” describes the changes in LV
mass, volume, shape, and composition of the ventricle in
response to the mechanical (stress and strain) and systemic
neurohormonal activation. Remodeling can be physiological
(as in normal growth of an organism, mild sustained
hypertension, or exercise training) or pathological (as in the
case of systolic heart failure). In either case, changes in the
volume and biology of the cardiac myocytes and/or changes
in the quantity and composition of the extracellular matrix
(ECM) underlie remodeling of the ventricular chamber (Table 1).
Remodeling can be observed in any of the 4 cardiac
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Myocardial Recovery December 18, 2012:2465–72chambers. Although a number of
reviews have summarized the
changes that occur at the cellular,
molecular, and anatomic level
during cardiac remodeling (4),
far fewer studies have focused on
the factors that allow the heart to
revert to normal LV size and
shape (i.e., reverse remodeling).
Insofar as the primary purpose of
this review is to focus on myo-
cardial recovery, we only discuss the biology of cardiac
remodeling briefly to provide the requisite background
for the subsequent discussion of the biology of reverse
remodeling and myocardial recovery (see reference [5] for
itations).
The changes that occur in the biology of the failing adult
ardiac myocyte include: 1) cell hypertrophy; 2) changes in
xcitation-contraction coupling leading to alterations in the
ontractile properties of the myocyte; 3) progressive loss of
yofilaments (myocytolysis); 4) -adrenergic desensitiza-
ion; 5) abnormal myocardial energetics secondary to mito-
hondrial abnormalities and altered substrate metabolism;
nd 6) progressive loss and/or disarray of the cytoskeleton.
ollectively these changes lead to decreased shortening and
elayed relaxation of the failing cardiac myocyte. The
lterations that occur in failing myocardium may be cate-
orized into those that occur in the volume of cardiac
yocytes as well as changes that occur in the volume and
omposition of the ECM. With respect to the changes that
ccur in the cardiac myocyte component of the myocar-
ium, there is increasing evidence to suggest that progres-
ive myocyte loss, via necrotic, apoptotic, or autophagic cell
eath pathways, may contribute to progressive cardiac dys-
unction and LV remodeling. What is less well understood
s the critical mass of functioning myocytes that is necessary
o maintain preserved LV pump function, as well as the
ontribution of stem cells (endogenous or bone marrow
erived) to maintaining this critical mass.
Changes within the ECM constitute the second impor-
ant myocardial adaptation that occurs during cardiac re-
odeling and include changes in overall collagen content,
he relative contents of different collagen subtypes, collagen
ross-linking, and connections between cells and the ECM
ia integrins. Furthermore, the 3-dimensional organization
f the ECM provides the physical scaffold that allows
ardiac myocytes to remain properly oriented and aligned
or the efficient transduction of myocyte shortening into
eveloped ventricular pressure. All of these essential features
f the ECM become altered and distorted in heart failure
econdary to alterations in collagen metabolism, which, in
urn, are due to changes in the balance between matrix
etalloproteinase inhibitors and activators and changes in
ollagen subtype expression. The changes that occur in the
iology of the cardiac myocyte as well as the myocardium
Abbreviations
and Acronyms
ECM  extracellular matrix
EDPVR  end-diastolic
pressure–volume
relationship
LV  left ventricular
LVAD  left ventricular
assist devicecardiocytes and ECM) lead to progressive LV dilation andncreased sphericity of the ventricle. The resultant increase
n LV end-diastolic volume along with concomitant LV
all thinning that can occur in some settings, set the stage
or progressive functional ventricular afterload mismatch
hat contributes further to a decrease in stroke volume.
oreover, the high end-diastolic wall stress might be
xpected to lead to: 1) hypoperfusion of the subendocar-
ium, with resultant ischemia and worsening of LV func-
ion; 2) increased oxidative stress with resultant activation of
amilies of genes that are sensitive to free radical generation
e.g., tumor necrosis factor and interleukin-1); and
3) sustained expression of stretch-activated genes (angioten-
sin II, endothelin, and tumor necrosis factor) and/or stretch
activation of hypertrophic signaling pathways. Increasing
LV dilation also results in tethering of the papillary muscles
with resultant incompetence of the mitral valve apparatus
and functional mitral regurgitation and further hemody-
namic overloading of the ventricle. Taken together, the
mechanical burdens that are engendered by LV remodeling
contribute to disease progression independent of the neu-
rohormonal status of the patient.
Reverse Remodeling
The term “reverse remodeling” was first used to describe the
leftward shift in the LV end-diastolic pressure-volume curve
of the failing heart after hemodynamic unloading with a left
ventricular assist device (LVAD) or a myocardial wrap with
the latissimus dorsi muscle (1,2). An important feature of
the decrease in LV size with reverse remodeling is that the
change in LV geometry persisted even if the inciting therapy
was abruptly stopped, suggesting that the change in prop-
erties reflected intrinsic biological changes in the LV cham-
ber as opposed to changes in LV volume that occur simply
Overview of Cardiac RemodelingTable 1 Overview of Cardiac Remodeling
Myocyte defects
Hypertrophy
Fetal gene expression
Beta-adrenergic desensitization
Myocytolysis
Excitation contraction coupling
Cytoskeletal proteins
Myocyte energetics
Myocardial defects
Myocyte death
Apoptosis
Necrosis
Autophagy
Alterations in extracellular matrix
Matrix degradation
Replacement fibrosis
Angiogenesis
Abnormal left ventricular geometry
Left ventricular dilation
Left ventricular wall thinningMitral valve incompetence
h
a
t
a
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December 18, 2012:2465–72 Myocardial Recoveryin response to a decrease in LV filling pressure. As shown in
Figure 1, reverse remodeling has been observed in a wide
variety of clinical settings, even when the severity of heart
failure is quite severe, including viral myocarditis and
postpartum cardiomyopathy or after removal of a cytotoxic
agent. There is also extensive clinical trial–based evidence
supporting the potential for reverse remodeling in patients
with chronic heart failure who have received medical,
device-based, and surgical interventions (reviewed in refer-
ences [6] and [7]). A recurring observation in all these clinical
studies/observations is that reverse remodeling is associated
Figure 1 Reverse Remodeling in Clinical Settings
Reverse remodeling is observed in a variety of clinical settings, as shown in
the middle ring of the diagram. The segments illustrated in the outermost
ring highlight the pathophysiological processes implicated by reverse remod-
eling in each particular clinical setting. ALM  acute lymphocytic myocardi-
tis; AVR  aortic valve replacement; CPAP  continuous positive airway
pressure; CRT  cardiac resynchronization therapy; CSD  cardiac support
device; LVAD  left ventricular assist device; MVR  mitral valve repair/
replacement; RAAS  renin-angiotensin-aldosterone system. Modified from
Hellawell and Margulies (6).
Cellular and Molecular Determinants of Reverse RemodelingTable 2 Cellular and Molecular Determinants of Reverse Remo
Beta-Blocker ACE Inhibitor A
Myocyte defects
Hypertrophy Decreased Decreased Dec
Fetal gene expression Decreased Decreased Dec
Myocytolysis Decreased Decreased Dec
Myocardial defects
Myocyte apoptosis Decreased Decreased Dec
MMP activation Decreased Decreased Dec
LV dilation Decreased Stabilized StabACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CRT  cardiac resynchroniz
device; MMP  matrix metalloproteinase.with an improvement in the clinical manifestations and
outcomes in heart failure, raising the interesting possibility
that reverse remodeling is linked mechanistically to the
observed improved heart failure outcomes.
Although the precise cellular and molecular mechanisms
that are responsible for the return toward normal LV size
and shape during reverse remodeling are not completely
understood, there is a fairly consistent biological theme with
respect to the parameters that return toward baseline after
pharmacological or device therapy (see the Online Appendix
for full citations). As shown in Table 2, there is a series of
favorable changes in cardiac myocyte biology, the composi-
tion of the myocardium, and the chamber properties of the
left ventricle after pharmacological and device therapies that
lead to reverse remodeling. With respect to the changes that
occur in cardiac myocyte biology, clinical studies of patients
undergoing LVAD implantation or cardiac resynchroniza-
tion therapy have consistently shown a decrease in cardiac
myocyte hypertrophy. The morphological changes in car-
diac myocyte size are accompanied by changes in gene
expression, including reversal of the abnormal fetal gene
program, genes involved in sarcomerogenesis, -adrenergic
signaling, the cytoskeleton, and/or return of excitation
contraction coupling genes toward expression levels ob-
served in nonfailing hearts in clinical situations in which
patients have been treated with beta-blockers, LVADs,
cardiac resynchronization therapy, or cardiac contractility
modulation. The decrease in cardiac myocyte cell size after
LVAD support is accompanied by changes in the proteome
as well, including changes in activation and/or activity levels
of protein kinases linked to cell growth, including extracel-
lular regulated kinase-1 and -2 and p38, whereas activation/
activity levels of Akt and GSK-3 (a negative regulator of
ypertrophy) are unchanged. Treatment with beta-blockers
nd LVAD support results in decreased hyperphosphoryla-
ion of the ryanodine receptor, which has been implicated in
calcium leak from the sarcoplasmic reticulum in failing
earts and hence contractile dysfunction. Normalization of
-adrenergic receptor density and enhanced inotropic re-
sponsiveness to isoproterenol have been demonstrated in
LVAD-supported failing hearts. Similar findings have been
observed after cardiac resynchronization therapy. Last, he-
Aldosterone LVAD CRT CSD
Decreased Decreased Decreased Decreased
Decreased Decreased Decreased
Decreased Decreased Decreased
Decreased Decreased Decreased
Decreased Decreased Decreased
Stabilized Decreased Decreased Decreaseddeling
RB
reased
reased
reased
reased
reased
ilizedation therapy; CSD  cardiac support device; LV  left ventricular; LVAD  left ventricular assist
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toration of more normal levels of sarcomeric and cytoskel-
etal proteins and organization. Collectively, the above
genomic and proteomic changes would be expected to lead
to functional improvements in the failing cardiac myocyte.
Indeed, there is a significant increase in contractility (max-
imal calcium saturated force generation) in cardiac myocytes
isolated from hearts that have undergone LVAD support
compared with myocytes isolated before LVAD support.
In addition to the changes in the biology of the adult
cardiac myocyte that occur during reverse remodeling, there
are a number of important changes that occur within the
myocardium, including changes in the ECM and microvas-
cular density (angiogenesis). Intuitively, restoration of
ECM content and organization would appear to be critical
with respect to facilitating the normalization of LV struc-
ture and function after LVAD support. Unfortunately, there
is very limited information on this complex topic, and what
little information exists is largely phenomenological in
nature. Even at the phenomenological level, there was
controversy initially concerning the simple question of how
total collagen content changes during LVAD support.
Some groups reported a decrease in total collagen, whereas
other groups reported an increase. One potential resolution
to the controversy came with recognition that collagen
content decreased in patients taking angiotensin-converting
enzyme inhibitors and increased in patients not taking
angiotensin-converting enzyme inhibitors, consistent with
previous observations that tissue levels of angiotensin II, a
profibrotic peptide, were increased in patients supported
with LVADs.
Myocardial microvascularity density is reduced in heart
failure and has been implicated in contractile dysfunction
and cardiac remodeling in heart failure. Although morpho-
logical and functional data are relatively limited, the extant
literature suggests that hemodynamic unloading leads to
up-regulation of angiogenesis-related genes and increased
microvascular density. However, the functional significance
of these findings is unclear given that coronary flow reserve
remains impaired after LVAD support.
Finally, improvements in the EDPVR seen with thera-
pies that induce reverse remodeling do not necessarily
equate with improvements in all aspects of the complex
structure of the ventricular chamber. For example, it has
been shown that although significant improvements can be
detected in the EDPVR after as little as 30 days of
support, these changes occur without any appreciable
change in the chamber radius-to-wall thickness ratio.
Myocardial Recovery
For some etiologies of heart failure, most notably acute
lymphocytic myocarditis (8) and peripartum cardiomyopa-
thy (9), spontaneous recovery from heart failure symptom-
atology and normalization of LV structure and function
occur spontaneously in 40% to 50% of patients. Moreover,similar rates of recovery have been reported for cessation/
removal of toxic substances, such as ethanol and anthracy-
clines, and/or reversal of energetically unfavorable conditions
such as tachycardia, transient ischemia, and hyperthyroidism
(reviewed in reference [6]). These statements notwithstand-
ing, the natural history of patients undergoing spontane-
ous myocardial recovery is not at all well characterized.
Interestingly, although hemodynamic unloading of the
heart in patients with more advanced heart failure leads to
reverse remodeling and partial reversal of many aspects of
the molecular and cellular heart failure phenotype, the
incidence of myocardial recovery is at best 15% (n  120) in
the selected cohorts of patients that have been reported (Table 3)
(Online Appendix) (10,11). Of note, the latest annual
report from Interagency Registry for Mechanically Assisted
Circulatory Support, which summarized results of 4,366
LVAD recipients from June 2006 to June 2011, reported a
1.4% rate of LVAD explantation for myocardial recovery
(12). Thus, although reverse remodeling occurs in the vast
majority of patients on prolonged LVAD support and is a
sine qua non for myocardial recovery, reverse remodeling
only rarely results in myocardial recovery. This then raises
the important question of why reverse remodeling and
myocardial recovery do not have the same clinical outcomes,
despite the fact that they involve very similar biological
processes.
One potential explanation for this important question
comes from a closer inspection of the terminology used to
describe these 2 clinical scenarios. The term “reverse remod-
eling,” as it is currently used, describes the biological process
of reversal of the cellular, myocardial, and anatomic abnor-
malities that occur in the remodeled ventricle. The clinical
literature reviewed herein suggests that patients may expe-
rience 1 of 2 potential outcomes for this biological process:
1) freedom from future heart failure events and 2) recur-
rence of heart failure events. Based on these 2 different
outcomes of reverse remodeling, we suggest that the term
“myocardial recovery” should be used describe the normal-
ization of the molecular, cellular, myocardial, and LV
geometric changes in the heart that provoke cardiac remod-
eling that allow the heart to maintain preserved LV struc-
ture/function in the face of normal and/or perturbed hemo-
dynamic loading conditions (13). Accordingly, myocardial
recovery is associated with freedom from future heart failure
events. We suggest that the term “myocardial remission”
should be used to refer to the normalization of the molec-
ular, cellular, myocardial, and LV geometric changes that
provoke cardiac remodeling that are insufficient to prevent
the recurrence of heart failure in the face of normal and/or
perturbed hemodynamic loading conditions. Thus, al-
though myocardial remission may be associated with stabi-
lization of the clinical course of heart failure as well as
reversal of many aspects of the heart failure phenotype, it is
not associated with freedom from future heart events.
Are these 2 terms merely semantic or are there potential
biological mechanisms that might explain why reverse
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namely, remission and recovery? Multiple lines of evidence
support the point of view that in most instances, reverse
remodeling does not lead to a normal heart, despite reversal
of many aspects of the heart failure phenotype. First, gene
expression profiling studies have shown that only 5% of
genes that are dysregulated in failing hearts revert apprecia-
bly to normal after LVAD support, despite typical morpho-
logical and functional responses to LVAD support (14,15).
Second, although maximal calcium-saturated force genera-
tion is improved in myocytes after LVAD support, force
generation is still less than in myocytes from nonfailing
controls, despite reversal of cardiac myocyte hypertrophy
(16). Third, as noted previously, the majority of studies that
examined changes in the ECM after LVAD suggested that
the ECM does not revert to normal on its own and can
actually be characterized by increased myocardial fibrosis.
Moreover, our current understanding of changes in the
ECM during LVAD support focuses on ECM content and
not on the more fundamental issues of its 3-dimensional
organization or with the interactions between the collagen
matrix and the resident cardiac myocytes, which are likely to
be critically important. Fourth, although the LV EDPVRs
of LVAD-supported hearts are shifted leftward and overlap
those found in nonfailing ventricles, the ratio of LV wall
thickness–to–LV wall radius does not return to normal
despite normalization of LV chamber geometry (17).
ather, this chamber radius–to–wall thickness ratio remains
levated at nearly twice normal. This has important impli-
ations for LV function, insofar as LV wall stress depends
Outcome Studies on Bridge to RecoveryTable 3 Outcome Studies on Bridge to Recovery
Study, Year(s) Design N
Adjuvant
Antiremodeling
Drug Protocol
Protocol for
Monitoring
Cardiac Function
U.S multicenter, 2007 P 67 Not standardized Yes
Berlin group, 2008,
2010–2012, 2010
R 188 Not standardized Yes
Harefield group, 2006 P 15 Yes Yes
Harefield group, 2011 P 20 Yes Yes
University of Athens-
Harefield group, 2007
P 8 Yes Yes
Gothenburg group, 2006 P 18 Not standardized Yes
Pittsburgh group, 2003 R 18 Not standardized Yes
Osaka group, 2005 R 11 Not standardized N/A
Pittsburgh group, 2010 R 102 N/A N/A
Multicenter, 2001 R 271 N/A N/A
Columbia group, 1998 R 111 N/A N/A
*A fifth patient fulfilled recovery criteria (5 of 8, 62.5%) but died of stroke just before left ventricu
and in reference (20). Modified from Drakos et al. (20).
HF  heart failure; N/A  not available; P  prospective studies; R  retrospective studies; Txritically on this ratio (Laplace’s law). Given that end-diastolic wall stress represents the load on the cardiac
myocyte at the onset of systole, the observation that the
chamber radius–to–wall thickness ratio is not normalized
despite the normalization of LV global chamber properties
suggests that the cardiac myocytes in reverse remodeled
ventricles are still exposed to increased physiological
stresses. Whether this represents loss of functioning cardiac
myocytes or failure of the 3-dimensional organization of the
ECM to revert to normal is unknown. Thus, the regression
of the heart failure phenotype and the accompanying return
toward a more normal cardiac phenotype during reverse
remodeling does not, in and of itself, signify that the
cellular/molecular biology and physiology of these hearts is
normal, which may explain why reverse remodeling may be
associated with different clinical outcomes.
Are there potential biological differences that may explain
the disparate clinical outcomes that occur after reverse
remodeling? Although the potential biological differences
between myocardial recovery and myocardial remission are
not known, there are parallels in mechanical engineering
science that may help to illuminate potential important
differences as well as to frame future mechanistic discus-
sions. In mechanics, deformation of a material refers to the
change in the shape or size of an object due to an applied
force. Figure 2A shows an example of a stress versus strain
diagram of a material that is exposed to an increased load.
With increasing stress, there is an increase in the length of
the material until the point when no further changes in
length are possible without the material breaking. Impor-
tantly, if the material returns to its original state when the
loading
ration,
onths
Recovery, n (%)
HF Recurrence/Follow-UpOverall Nonischemic
4.5 6 (9) 5 (13.5) Freedom from death or Tx 100%/6 months
4.3 35 (18.6) 35 (18.6) Freedom from recurrent HF 74% and
66%/3 and 5 yrs, respectively
10.6 11 (73) 11 (73) Freedom from recurrent HF 100% and
89%/1 and 4 yrs, respectively
9.5 12 (60) 12 (60) Freedom from recurrent HF
83.3%/3 yrs
–10 4* (50) 4* (50) Freedom from recurrent HF 100%/2 yrs
6.7 3 (17) 3 (20) Freedom from recurrent HF or Tx
33%/8 yrs
7.8 6 (33) 5 (38) Freedom from recurrent HF 67%/1 yr
15.1 5 (45) 5 (45) Freedom from recurrent HR
100%/8–29 months
4.9 14 (13.7) 14 (13.7) Freedom from recurrent HF or death
71.4%/5 yrs
1.9 22 (8.1) 22 (8.1) Freedom from recurrent HF or death
77%/3.2 yrs
6.2 5 (4.5) 4 (8) Freedom from recurrent HF or death
20%/15 months
ist device explantation. Full references for the above studies are provided in the Online Appendix
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Myocardial Recovery December 18, 2012:2465–72contrast, if during the application of stress the mechanical
properties of the material are changed irreversibly, such that
the object will return only part way to its original shape
when the stress is removed, this is referred to as plastic
deformation. It is sometimes the case that elastic deforma-
tion occurs under a certain level of stress and plastic
deformation occurs when that stress level is exceeded.
Regardless, the important distinction is whether the mate-
rial returns to its original state when the stress is removed.
Although precise parallels between cardiac remodeling in
heart failure and deformation of solid materials after loading
are not appropriate, there could be a heuristic parallel
between reverse remodeling and plastic deformation, inas-
much as the reverse remodeled heart does not revert
completely to normal after cessation of hemodynamic over-
loading (Fig. 2B). Although speculative, it is possible that
myocardial recovery is more analogous to elastic deforma-
tion in that the recovered heart reverts to normal after
hemodynamic overloading is removed (Fig. 2C). Thus, we
propose that reverse remodeling without recovery represents
a reversal of the heart failure phenotype that occurs in hearts
that have sustained irreversible damage, whereas myocardial
recovery represents a reversal of the heart failure phenotype
that occurs in hearts that have reversible damage (Fig. 3).
lthough the biological motifs that separate reversible
elastic) from irreversible (plastic) changes in the heart are
ot known, it is likely that the progressive loss of cardiac
yocytes, irreversible changes at the DNA level, and the
rogressive erosion of the native 3-dimensional organization
f the ECM surrounding the cardiac myocytes will be
ritical determinants that distinguish between reverse re-
odeling and myocardial recovery (5,13). The observation
hat the great majority of clinical examples of myocardial
ecovery in the literature occur after transient injury (e.g.,
iral infection, inflammation, toxic injury) rather than more
ong-standing and/or permanent injury (e.g., myocardial
nfarction, genetic abnormalities) is consistent with the
oint of view that the ability of the heart to “recover” is
Figure 2 Mechanical Engineering Science and Cardiac Remode
(A) Diagram of a stress-strain curve of a ductile material, illustrating the relations
reversible changes in a material (elastic deformation) if the properties of the mate
(B) Hypothetical model of reverse remodeling in a heart that has undergone irreve
recovery in a heart that has undergone reversible damage (elastic deformation). Lelated to the nature of the inciting injury and the extent ofunderlying myocardial damage that occurs during the reso-
lution of cardiac injury. This observation is also consistent
with the observation from the LVAD bridge to recovery
studies (Table 3), which have consistently shown that
recovery is possible in patients with myocarditis and/or
postpartum cardiomyopathy, whereas recovery does not
occur in patients with irreversible damage from myocardial
ischemia/infarction. It is also possible that myocardial re-
covery may represent a new and unique set of biological
adaptations (e.g., changes in integrin signaling and
tween an applied force (stress) and deformation (strain). Deformation can lead to
e not changed and irreversible changes in a material (plastic deformation).
damage (plastic deformation). (C) Hypothetical model of reverse remodeling with
ft ventricular.
Figure 3 Reverse Remodeling and Myocardial Recovery
Cardiac remodeling arises secondary to abnormalities that arise in the biology
of the cardiac myocyte (C), the myocardium (cardiocytes and extracellular
matrix [M]), as well as LV geometry, which have collectively been referred to as
the heart failure (HF) phenotype. During reverse remodeling, there is a reversal
of the abnormalities in the cardiac myocyte as well as the extracellular matrix,
leading to a reversal of the abnormalities in left ventricular (LV) geometry.
Reverse remodeling can lead to 2 clinical outcomes: 1) myocardial recovery,
characterized by freedom from future cardiac events; or 2) myocardial remis-
sion, which is characterized by recurrence of heart failure events.ling
hip be
rial ar
rsible
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function and improved prognosis and that these unique
adaptations explain the differences between myocardial re-
covery and remission (6,18,19).
Conclusions and Future Directions
As discussed here, the failing heart is capable of undergoing
favorable changes in LV volume and mass and to assume a
more normal energetically favorable elliptical shape (reverse
remodeling). Although the various components of reverse
remodeling have been carefully studied and annotated, it is
unclear at present exactly how these changes contribute to
restoration of normal LV structure and function. That is, we
simply do not understand what the essential biological
“drivers” of myocardial recovery are, nor do we understand
how they are coordinated. More importantly, we do not
understand why reverse remodeling is sometimes associated
with freedom from recurrent heart failure events (i.e.,
myocardial recovery) and why reverse remodeling is some-
times associated with recurrence of heart failure events
(5,11). Indeed, the extant literature does not suggest which
of the myriad changes that occur during reversal of the heart
failure phenotype are most important and/or necessary to
preserve LV structure and function in the long term. Here
we suggest that reverse remodeling represents a multilevel
(molecular, cellular, anatomic) reversal toward a normal
myocardial phenotype and that this reversal of phenotype is
accompanied by 2 different outcomes, namely, myocardial
recovery and myocardial remission. We propose that the
difference between these 2 outcomes (Fig. 3) is that myo-
cardial remission represents reversal of the heart failure
phenotype superimposed on hearts that have sustained
irreversible damage (plastic deformation), whereas myocar-
dial recovery represents reversal of the heart failure pheno-
type superimposed on hearts that have not sustained irre-
versible damage (elastic deformation). This formalism,
although hypothetical at present, can be validated experi-
mentally and clinically and permits certain predictions with
respect to identifying responders and nonresponders to
medical and device therapies. For example, one would not
expect myocardial recovery to occur in patients with ad-
vanced heart failure secondary to ischemic heart disease
(Table 3) or even patients with dilated cardiomyopathy
secondary to genetic cytoskeletal defects, whereas recovery
can be anticipated in appropriately selected subsets of
patients with recent-onset heart failure of reversible etiolo-
gies (Fig. 1). The quest for elucidating the biological basis
for these distinctions extends beyond intellectual curiosity or
the need to select appropriate patients for clinical trials.
Rather, insights into these distinctions will suggest new
heart failure therapies that directly target the phylogeneti-
cally conserved pathways that have evolved to repair the
myocardium rather than continuing to target signaling
pathways that attenuate remodeling. Given our current lack
of understanding of the biology of reverse remodeling andthe disparate outcomes of remodeling, it is likely that the
learning curve will be extremely steep, now and for the
foreseeable future.
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